Related Experiment Video
Updated: Mar 21, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
The Role of MDM2 Amplification and Overexpression in Tumorigenesis
Jonathan D Oliner1, Anne Y Saiki2, Sean Caenepeel2
1Jon Oliner Consulting, Garrett Park, Maryland 20896.
Abstract:
Mouse double minute 2 (MDM2) is a critical negative regulator of the tumor suppressor p53, playing a key role in controlling its transcriptional activity, protein stability, and nuclear localization. MDM2 expression is up-regulated in numerous cancers, resulting in a loss of p53-dependent activities, such as apoptosis and cell-cycle arrest. Genetic amplification and inheritance of MDM2 promoter single-nucleotide polymorphisms (SNPs) are the two best-studied mechanisms for up-regulating MDM2 activity. This article provides an overview of these events in human cancer, highlighting the frequent occurrence of MDM2 amplification in sarcoma and the role of SNP309 and SNP285 in regulating MDM2 expression and cancer risk. The availability of large-scale genomic profiling datasets, like those from The Cancer Genome Atlas Research Network, have provided the opportunity to evaluate the consequences of MDM2 amplification and SNP inheritance across high-quality tumor samples from diverse cancer indications.
Insights
Mouse double minute 2 (MDM2) negatively regulates tumor suppressor p53. MDM2 amplification and promoter single-nucleotide polymorphisms (SNPs) are key mechanisms driving cancer by reducing p53 activity.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mouse double minute 2 (MDM2) is a crucial negative regulator of the tumor suppressor p53.
- MDM2 controls p53's transcriptional activity, protein stability, and nuclear localization.
- Elevated MDM2 expression is observed in many cancers, leading to impaired p53 functions like apoptosis and cell-cycle arrest.
Purpose of the Study:
- To provide an overview of MDM2 amplification and promoter single-nucleotide polymorphisms (SNPs) in human cancer.
- To highlight the role of MDM2 amplification in sarcoma and the impact of SNPs (SNP309, SNP285) on MDM2 expression and cancer risk.
Main Methods:
- Review of genetic amplification and promoter single-nucleotide polymorphisms (SNPs) in human cancer.
- Analysis of large-scale genomic profiling datasets, including The Cancer Genome Atlas (TCGA).
- Evaluation of MDM2 amplification and SNP inheritance across diverse cancer types.
Main Results:
- MDM2 amplification is frequently observed in sarcoma.
- Specific SNPs, such as SNP309 and SNP285, influence MDM2 expression levels.
- These genetic alterations contribute to cancer development by disrupting p53 pathway.
Conclusions:
- MDM2 amplification and specific promoter SNPs are significant mechanisms in human oncogenesis.
- Understanding these genetic events is crucial for evaluating cancer risk and developing targeted therapies.
- Genomic profiling data provides valuable insights into the role of MDM2 in various cancers.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Mitogens and the Cell Cycle
Master Transcription Regulators
Induced Pluripotent Stem Cells
Somatic...

